From Alphastreet - Earnings Decoded. Market Intelligence Delivered · Newsdesk · · 1m 30s
X4 Pharmaceuticals Extends Commercial Runway
X4 Pharmaceuticals secures $150m debt facility to extend commercial runway for XOLREMDI and mavorixafor.
In brief
X4 Pharmaceuticals secures $150m debt facility to extend commercial runway for XOLREMDI and mavorixafor. X4 Pharmaceuticals secured a $150 million debt facility with K2 HealthVentures to extend its commercial runway while awaiting pivotal 4WARD trial results. Originally reported by Alphastreet - Earnings Decoded…
X4 Pharmaceuticals secures debt facility
X4 Pharmaceuticals secured a senior debt facility of up to $150 million with K2 HealthVentures on October 8, 2026.
XOLREMDI approved for WHIM syndrome
XOLREMDI is approved in the U.S. as an oral, once-daily therapy to increase circulating mature neutrophils and lymphocytes in patients 12 years and older with WHIM syndrome.
4WARD trial enrollment target
X4 expects to complete enrollment in the global pivotal Phase 3 4WARD trial by year-end 2026 and report topline data in the first half of 2028.
Q2 2026 financial results
X4 reported a net loss of $16.2 million for the quarter ended June 30, 2026, compared with $25.7 million in the prior-year period.
Debt facility structure details
The K2 facility provides term loans of up to $150 million with the first tranche of $80 million funded at closing to repay prior obligations.
Interest terms and conditions
Loans carry cash interest at a variable annual rate equal to the greater of 8.55% or Wall Street Journal prime rate plus 1.55%, with interest-only payments through October 1, 2029.
Investor watch items
X4’s commercial trajectory, 4WARD timeline, and access to the remaining $70 million under the K2 facility are key investor watch items.
In short
X4 Pharmaceuticals secured a $150 million debt facility with K2 HealthVentures to extend its commercial runway while awaiting pivotal 4WARD trial results.
